RA Capital Management 13F holdings, Q1 2009
Holdings as of March 31, 2009 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 12 US equity positions worth $184.4m in its Q1 2009 13F filing. The largest position was SEQUENOM INC at 62.6% of the reported book, followed by BSTC and ARDEA BIOSCIENCES INC. Against the Q4 2008 filing, it opened 7 new positions, added to 1 and reduced 4 among the top 12 holdings.
What did RA Capital Management own in Q1 2009? Top 12 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2008 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 62.6% | $115.5m | 8,119,580 | 7% | added | |
| 2 | BSTC BIOSPECIFICS TECHNOLOGIES CO | 9.0% | $16.6m | 810,931 | – | new | |
| 3 | ARDEA BIOSCIENCES INC | 6.5% | $12.0m | 1,165,262 | -22% | reduced | |
| 4 | AMAG AMAG PHARMACEUTICALS INC | 6.1% | $11.2m | 305,163 | -16% | reduced | |
| 5 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 5.3% | $9.7m | 339,044 | -1% | reduced |
| 6 | PHARMASSET INC | 4.0% | $7.5m | 760,694 | -46% | reduced | |
| 7 | CUBIST PHARMACEUTICALS INC | 2.7% | $4.9m | 300,000 | – | new | |
| 8 | ANADYS PHARMACEUTICALS INC | 1.2% | $2.2m | 329,725 | – | new | |
| 9 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 1.0% | $1.8m | 2,019,170 | – | new |
| 10 | CARDIOME PHARMA CORP | 0.7% | $1.3m | 438,915 | – | new | |
| 11 | ENTEROMEDICS INC | 0.6% | $1.1m | 824,742 | – | new | |
| 12 | DENDREON CORP | 0.3% | $578.0k | 137,500 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.